| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Gyre Therapeutics, Inc. (GYRE) has 6 insiders with recent SEC Form 4 filings, including 10 buys and 0 sells. GYRE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 2.57M | $15.72M | - | |
| 10% | 2.14M | $13.14M | - | |
| CFO | 95.1K | $582.7K | - | |
| Dir | 52.0K | $318.8K | - | |
| CFO | 50.0K | $306.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 9, 2021 | Levy Howard | Chief Medical Officer | Buy | 639 | $3.62 | $2,313.18 | New | -26.5% | -57.0% | |
| Aug 9, 2021 | Blouse Grant E.51 | Chief Scientific Officer | Buy | 1,163 | $3.62 | $4,210.06 | +66.3% | -26.5% | -57.0% | |
| Feb 9, 2021 | Usman Nassim67 | President &CEO | Buy | 582 | $4.81 | $2,799.42 | +5.0% | - | - | |
| Feb 9, 2021 | Levy Howard | Chief Medical Officer | Buy | 1,670 | $4.81 | $8,032.70 | +7.7% | - | - | |
| Aug 10, 2020 | Usman Nassim67 | President &CEO | Buy | 582 | $4.81 | $2,799.42 | +5.3% | - | - | |
| Aug 10, 2020 | Levy Howard | Chief Medical Officer | Buy | 1,768 | $4.81 | $8,504.08 | +70.7% | - | - | |
| Mar 16, 2020 | Levy Howard | Chief Medical Officer | Buy | 2,500 | $4.05 | $10,131.50 | New | - | - | |
| Mar 13, 2020 | Usman Nassim67 | President &CEO | Buy | 4,000 | $3.91 | $15,647.20 | +57.1% | - | - | |
| Mar 13, 2020 | Cai Veronica | Controller | Buy | 2,000 | $4.11 | $8,220.00 | +37.4% | - | - | |
| Mar 13, 2020 | Richard John P | Director | Buy | 2,500 | $3.98 | $9,950.00 | +205.6% | - | - |